DexCom, Inc. (DXCM) EVP Donald Abbey Sells 7,653 Shares
DexCom, Inc. (NASDAQ:DXCM) EVP Donald Abbey sold 7,653 shares of the business’s stock in a transaction dated Tuesday, March 12th. The stock was sold at an average price of $142.79, for a total transaction of $1,092,771.87. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink.
NASDAQ DXCM opened at $146.85 on Friday. The company has a quick ratio of 7.32, a current ratio of 7.64 and a debt-to-equity ratio of 1.52. The stock has a market capitalization of $12.94 billion, a price-to-earnings ratio of 489.50 and a beta of 0.78. DexCom, Inc. has a 12-month low of $64.15 and a 12-month high of $156.16.
DexCom (NASDAQ:DXCM) last posted its quarterly earnings data on Thursday, February 21st. The medical device company reported $0.54 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.16 by $0.38. The firm had revenue of $338.00 million during the quarter, compared to the consensus estimate of $331.60 million. DexCom had a negative net margin of 12.32% and a positive return on equity of 4.98%. The business’s revenue for the quarter was up 52.9% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.10 EPS. On average, research analysts forecast that DexCom, Inc. will post 0.46 EPS for the current fiscal year.
Several research firms have recently weighed in on DXCM. BidaskClub upgraded shares of DexCom from a “hold” rating to a “buy” rating in a research note on Friday, December 28th. Canaccord Genuity boosted their price objective on shares of DexCom from $140.00 to $160.00 and gave the stock a “buy” rating in a research note on Friday, February 22nd. Oppenheimer restated a “buy” rating on shares of DexCom in a research note on Wednesday, November 21st. Cowen upped their price target on shares of DexCom from $150.00 to $175.00 and gave the company an “outperform” rating in a research note on Friday, February 22nd. Finally, UBS Group upped their price target on shares of DexCom from $135.00 to $140.00 and gave the company a “neutral” rating in a research note on Tuesday, January 8th. Seven analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and one has issued a strong buy rating to the company. The company currently has a consensus rating of “Buy” and an average target price of $149.53.
ILLEGAL ACTIVITY NOTICE: This piece of content was originally posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this piece of content on another site, it was illegally stolen and reposted in violation of US & international copyright & trademark legislation. The original version of this piece of content can be viewed at https://www.thecerbatgem.com/2019/03/15/dexcom-inc-dxcm-evp-donald-abbey-sells-7653-shares.html.
DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for ambulatory use by people with diabetes; and for use by healthcare providers. Its products include DexCom G5 mobile continuous glucose monitoring system to communicate directly to patient's mobile device; DexCom G4 PLATINUM system for continuous use by adults with diabetes; and DexCom Share, a remote monitoring system.
Featured Story: Do You Need a Fiduciary?
Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.